CN1168496C - Powder mist for pulmonary administration of insulin and preparation method thereof - Google Patents
Powder mist for pulmonary administration of insulin and preparation method thereof Download PDFInfo
- Publication number
- CN1168496C CN1168496C CNB021125139A CN02112513A CN1168496C CN 1168496 C CN1168496 C CN 1168496C CN B021125139 A CNB021125139 A CN B021125139A CN 02112513 A CN02112513 A CN 02112513A CN 1168496 C CN1168496 C CN 1168496C
- Authority
- CN
- China
- Prior art keywords
- insulin
- powder
- spray
- preparation
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims abstract description 252
- 102000004877 Insulin Human genes 0.000 title claims abstract description 127
- 108090001061 Insulin Proteins 0.000 title claims abstract description 127
- 229940125396 insulin Drugs 0.000 title claims abstract description 126
- 239000000843 powder Substances 0.000 title claims abstract description 66
- 238000002360 preparation method Methods 0.000 title claims description 22
- 230000002685 pulmonary effect Effects 0.000 title description 18
- 239000003595 mist Substances 0.000 title 1
- 238000001694 spray drying Methods 0.000 claims abstract description 23
- 239000007788 liquid Substances 0.000 claims abstract description 11
- 229940098458 powder spray Drugs 0.000 claims description 49
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 19
- 229930195725 Mannitol Natural products 0.000 claims description 19
- 235000010355 mannitol Nutrition 0.000 claims description 19
- 239000000594 mannitol Substances 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 239000004473 Threonine Substances 0.000 claims description 14
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 13
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 13
- 235000005772 leucine Nutrition 0.000 claims description 11
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 8
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 4
- 229930182844 L-isoleucine Natural products 0.000 claims description 4
- 229960000310 isoleucine Drugs 0.000 claims description 4
- 150000002614 leucines Chemical class 0.000 claims description 3
- 239000002075 main ingredient Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 23
- 239000003814 drug Substances 0.000 abstract description 16
- 239000002245 particle Substances 0.000 abstract description 13
- 150000001413 amino acids Chemical class 0.000 abstract description 12
- 230000008569 process Effects 0.000 abstract description 9
- 210000004072 lung Anatomy 0.000 abstract description 4
- 238000005507 spraying Methods 0.000 abstract 2
- 239000002775 capsule Substances 0.000 description 31
- 239000000243 solution Substances 0.000 description 27
- 239000008280 blood Substances 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 20
- 238000012360 testing method Methods 0.000 description 19
- 241000700159 Rattus Species 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 238000010521 absorption reaction Methods 0.000 description 13
- 239000007921 spray Substances 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 229940024606 amino acid Drugs 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 11
- 239000002904 solvent Substances 0.000 description 10
- 229960002898 threonine Drugs 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 150000005846 sugar alcohols Chemical class 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 238000000889 atomisation Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000005352 clarification Methods 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 239000012982 microporous membrane Substances 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- 210000003437 trachea Anatomy 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010006458 Bronchitis chronic Diseases 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 206010006451 bronchitis Diseases 0.000 description 3
- 208000007451 chronic bronchitis Diseases 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 239000007902 hard capsule Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 229930064664 L-arginine Natural products 0.000 description 2
- 235000014852 L-arginine Nutrition 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 229960005261 aspartic acid Drugs 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 238000001033 granulometry Methods 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 101001012217 Conus geographus Con-Ins G3 Proteins 0.000 description 1
- 101001012221 Conus tulipa Con-Ins T3 Proteins 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- HZYCAKGEXXKCDM-UHFFFAOYSA-N Methyl 2-(methylthio)acetate Chemical compound COC(=O)CSC HZYCAKGEXXKCDM-UHFFFAOYSA-N 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 108010076181 Proinsulin Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- YAJCHEVQCOHZDC-QMMNLEPNSA-N actrapid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3N=CNC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@H](C)CC)[C@H](C)CC)[C@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C(N)=O)C1=CNC=N1 YAJCHEVQCOHZDC-QMMNLEPNSA-N 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- -1 mannitol Chemical class 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229940127017 oral antidiabetic Drugs 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011027 product recovery Methods 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to an insulin powder-spraying prescription which can be absorbed at lungs after being sucked from mouths, and a preparing method thereof. The insulin powder-spraying prescription mainly comprises insulin, polyhydroxy glucol and amino acids. During spray-drying, the concentration of medicine liquid is 0.1 to 5%, the spray-drying temperature in mouths is 100 to 120 DEG C, the temperature outside the mouths is 60 to 70 DEG C, and the flow velocity of a nozzle is 800 L/H. The prepared insulin has the advantages of small powder particle diameter, light weight and good solubility, bulk density, rest angle and atomizing performance, and is difficult to absorb moisture in the using process.
Description
Technical field
The present invention relates to a kind of insulin powder spray and preparation method thereof, but bring into play insulin powder spray of drug effect and preparation method thereof in pulmonary's absorption after especially per os sucks.
Background technology
A kind of 54 peptide compounds that insulin (Insulin) produces for pancreas, it act as the involved in sugar metabolism.Under pathological state, islet cells can not be secreted the insulin of q.s, and at this moment blood sugar concentration will raise, and causes diabetes.Secular hyperglycemia state not only make patient body become thin, weak, also can bring out other disease, as cataract, apoplexy, myocardial infarction, nephropathy etc.According to WHO statistics, nineteen ninety-five the whole world have 1.35 hundred million populations to suffer from diabetes, wherein in state-owned 1,600 ten thousand people, and sickness rate has ascendant trend year by year at present.Expect the whole world in 2025 and will reach 300,000,000 people, will there be 3,800 ten thousand diabeticss in China.
Traditionally diabetes are divided into 1 type (insulin-dependent) and 2 types (non-insulin-depending type).For type 1 diabetes, must treat by supplementation with insulin.To type 2 diabetes mellitus, clinical mainly with the treatment of dietetic therapy and oral antidiabetic drug, but patient's sensitivity reduces (clinical title " secondary failure ") during the life-time service antidiabetic drug, and also must give insulin this moment.The route of administration of insulin is mainly vein or subcutaneous injection at present, and long-term prescription is made troubles to patient and be painful.
The insulin non-injection administration is one of great and popular research topic of international the world of medicine always, the research of other dosage form beyond the inhalant is comprised: eye drop, intranasal administration, transdermal administration, mouth mucosa drug administration, rectally and oral administration etc.But be that non-injecting pathway has a maximum disadvantage that is difficult to overcome, promptly absorb slowly that peak concentration of drug is low, all can not compare, be not suitable for diabetes patient's clinical treatment with injection.
Pulmonary's inhalation is one of comparatively ideal route of administration.At first the degree of absorption of pulmonary administration is better, and not only aerosolized medicaments is very slow from the process of base of lung elimination, avoids being similar to the gastrointestinal destruction, and has reduced the first pass effect of medicine, improves bioavailability of medicament.Secondly, insulin is very fast from the speed that pulmonary absorbs, and can form higher pulse concentration, meet the normal need of the release characteristic and the human body of endogenous insulin, thereby can in diet, use, the shortcoming of having avoided some dosage form to use 2 hours ante cibum makes medication convenient.
The dosage form of pulmonary's inhalation can be divided into aerosol (comprising solution-type and suspension type), powder spray and spray.Because the chemical stability of insulin in water is relatively poor, does not dissolve in ethanol and fluorine-containing propellant, difficulty is made liquid type aerosol or spray.Suspension aerosol physical stability poor (microgranule is easily assembled), the easy obstruction of quantitative valve etc.
The drug loading of powder spray is big, but because the particularity of pulmonary administration, must be little with good water solubility, zest, the adjuvant of good biocompatibility.In order to promote the absorption of insulin in pulmonary, there is document to be disclosed in and adds surface activity or penetration enhancers in the powder spray, among the CN1129904A disclosed insulin inhaled dose, contain sorbefacient surfactant, as Capric acid sodium salt, bile salts etc.But the life-time service surfactant can produce infringement to pulmonary.
As everyone knows, medicated powder will pass through the human organ passage that trachea, bronchus etc. are quite grown one section humidity from the oral cavity to the pulmonary, and too easily moisture absorption will be adsorbed in airway walls, does not arrive alveolar region, and too light, overflows with breathing easily again.So it is little of 1-5 μ m, opaque light (density is little), good fluidity (angle of repose is little) that the most important condition that pulmonary's induction type powder spray insulin will be brought into play drug effect is that the particle diameter of medicated powder is wanted, medicated powder could arrive alveolar and less exhalation ease is lost by the oral cavity.Particle diameter is little just easily to be absorbed in pulmonary.But, just because of the little surface area of medicated powder particle diameter is big, so generally speaking very easily moisture absorption of powder itself.This is a very serious problem.No matter how little particle diameter is, must affect the treatment in case form piece after the moisture absorption.And, as do not have special utensil, patient to use powder inconvenient voluntarily yet.
According to the characteristics of dust cloud inhalant, the dissolubility of medicated powder, bulk density, angle of repose, atomization, moisture absorption change and are to reach that curative effect institute must consideration.
Summary of the invention
The technical problem to be solved in the present invention is: prepare a kind of insulin powder spray, select carrier with the insulin compatibility, make that the insulin powder diameter that obtains is little, opaque is light, not only the dissolubility of medicated powder, bulk density, angle of repose, atomization are all better, and are difficult for moisture absorption.
Select the technology of preparation insulin powder spray, so that insulin structure in preparation process is not destroyed, its powder diameter of the insulin powder spray that makes is little, opaque is light, not only the dissolubility of medicated powder, bulk density, angle of repose, atomization are all better, and are difficult for moisture absorption in processing, storage, use.
Select the splendid attire insulin powder for the pharmaceutical dosage form that the oral cavity sucks, not only can carry out suitability for industrialized production easily, and be easy to carry, inhalation dose is accurate during use, prevents inhale or few the suction more.
For solving above-mentioned task, the technical solution used in the present invention is:
A kind of insulin powder spray is characterized in that mainly being made up of following composition: insulin, alditol, aminoacid.
Above-mentioned insulin powder spray is characterized in that its Main Ingredients and Appearance proportioning (weight ratio, down together) is: 1 part of insulin, 6～7 parts of alditols, 0.5～3 part in aminoacid.
Above-mentioned insulin powder spray is characterized in that: alditol is mannitol or xylitol, and aminoacid is threonine, L-aspartic acid, L-glutamic acid, L-isoleucine, L-arginine and/or leucine.
Described insulin powder spray is characterized in that mainly being made up of following proportioning components: 1 part of insulin, 6～7 parts in mannitol, 0.5～3 part of threonine.
Described insulin powder spray is characterized in that mainly being made up of following proportioning components: 1 part of insulin, 7 parts in mannitol, 2 parts of leucines.
A kind of preparation method of insulin powder spray is mixed alditol, aminoacid with insulin, mixed liquid concentration is 0.1～5%, spray drying.
The preparation method of above-mentioned insulin powder spray, it is characterized in that: with 1 part of insulin, alditol 6-7 part and 0.5～3 part of mixing of aminoacid, mixed liquid concentration is 0.1～5%, and the spray drying inlet temperature is 100～120 ℃, outlet temperature is 60～70 ℃, nozzle flow velocity 800L/H.
The preparation method of described insulin powder spray, it is characterized in that: alditol is mannitol or xylitol, aminoacid is threonine, L-aspartic acid, L-glutamic acid, L-isoleucine, L-arginine and/or leucine, mixed liquid concentration is 1～2% preferably, the spray drying inlet temperature is 110 ℃, outlet temperature is 65 ℃, nozzle flow velocity 800L/H.
The preparation method preferably of insulin powder spray is: with 1 part of insulin, and 7 parts in mannitol, 2 parts of mixing of threonine, mixed liquid concentration is 1.7%, spray drying, the gained insulin powder incapsulates.
The another kind of described insulin powder spray preparation method preferably is: with 1 part of insulin, and 6 parts in mannitol, 3 parts of mixing of leucine, mixed liquid concentration is 1.6%, spray drying, the gained insulin powder incapsulates.
In the preparation insulin powder spray process, promote the insulin dissolving, can add organic acid or mineral acid routinely in order to make, for example citric acid, acetic acid and/or hydrochloric acid, the purpose that adds acid is to promote the insulin dissolving.After insulin dissolves under acid condition, can again pH be recalled to the neutrality, to reduce its stimulation to human body.Can use sodium citrate and/or sodium hydroxide, with pH regulator to 7.0～7.5, preferably with pH regulator to 7.4.In order to reach acidify or neutral purpose, also can use other acid, alkali or organic salt.
Use aminoacid such as threonine or leucine to cooperate with alditol such as mannitol, can produce good synergism to the residual quantity after dissolubility, bulk density, angle of repose, atomizing effect and the use of product, especially can reduce the hygroscopicity of insulin powder spray.When insulin was 1 part, aminoacid and alditol were at 6～7 parts: during 0.5～3 part proportion, anti-moisture sorption effect is good.
Table 1, table 2 are experiments of screening insulin powder spray prescription.
The prescription screening of the insulin inhaled powder spray of table 1.
Prescription 1 prescription 2 prescriptions 3 prescriptions 4 prescriptions 5
Insulin 5g 1.43g 1.43g 1.43g 1.43g
Mannitol 45g 13.5g 10.5g 00
Lactose 000 10.5g 0
Dextran 0000 10.5g
Threonine 00 3.0g 3.0g 3.0g
The matter dissolubility is defective qualified qualified defective
Amount bulk density 0.25 0.28 0.13 0.28 0.14
Comment 40.1 ° 41.3 ° 39.7 ° 38.3 ° 42.1 ° of angle of reposes
The medium excellent difference of valency atomizing effect is medium
Softgel shell powder residual quantity 8.2% 3.7% 2.6% 42.4% 38.6%
*The preparation technology of prescription 1 mixes the back with two components directly to pulverize
The situation of change of capsule under 75% relative humidity that each prescription of table 2 is made
| Prescription 1 | Prescription 2 | Prescription 3 | Prescription 4 | Prescription 5 | |
| Weightening finish | 1.1％ | 1.5％ | 1.5％ | 2.0％ | 4.2％ |
| Atomizing effect | Deposit has more granule | Deposit has a small amount of fine particle | Atomizing is good, with the fine-powdered uniform deposition | Deposit is block residual for the granule capsule has | It is block residual that deposit has the granule capsule to have |
| Residual quantity | 9.6％ | 5.2％ | 3.9％ | 62.9％ | 51.9％ |
Experimental data in table 1, the table 2 proves: use mannitol to do diluent separately, the water solublity of product is relatively poor, and the spray test effect is undesirable, capsule residual quantity more (prescription 1); After adding threonine again, opaque improves, and density reduces, and powder can form smog and uniform deposition during spray test, does not see graininess aggregation (prescription 3).Also with aminoacid and lactose or dextran assembly, effect is all bad in the experiment.Though lactose dissolubility, better mobile, easily moisture absorption, powder is gathered into bulk usually, atomizing effect poor (prescription 4); The dissolution velocity of dextran in normal-temperature water is slower, atomizing effect also bad (prescription 5).Determined the prescription of insulin powder spray of the present invention thus.
The test method and the evaluation criterion of listed each index of insulin powder spray are as follows in table 1, the table 2:
Dissolubility: get 2 of the insulin inhaled powder sprays of trial-production, open softgel shell, content is put into the test tube with ground stopper that 2ml water is housed, its dissolving situation is observed in jolting 1 minute.If powder can dissolve and the solution clarification, dissolubility is qualified; If show muddy, then dissolubility is defective.
Bulk density: after with analytical balance medicated powder being weighed, place little graduated cylinder, measure the volume of powder gently after the jolting, weight (g) is compared the bulk density that can obtain powder with volume (ml), bulk density with little be good.
Angle of repose: the measuring method of angle of repose is, get the about 6cm of bore, one in the little funnel of the about 0.4cm of caliber (internal diameter) is fixed on the iron stand, shop, funnel below a blank sheet of paper, the lower end of funnel and the height of paper are 4-5cm, slowly pour medicated powder into funnel from funnel top, medicated powder to be leaked down is measured the height and the lower end diameter of this medicated powder cone during near hopper outlet, calculate the tangent of an angle that stops in view of the above, and further calculate angle of repose.
Powder residual quantity and atomization: the insulin inhaled powder spray precision that will manufacture experimently weigh (W1), put into special-purpose inhaler (production of Shanghai balance pharmaceutical factory),, again inhaler is linked to each other with the 5000ml vial the capsule punching, the junction is equipped with switching knob, and this knob beginning is in the closed position.With 60l/min throughput evacuation, open above-mentioned knob, the medicated powder in the capsule promptly sprays from inhaler, continuous three times.If powder forms even smog, the no big granule in deposition back exists, and illustrates that atomization is good; If most of powder is atomized,, only there is small quantities of particles at the bottle end, and atomization is medium.If most of powder is not atomized, form bulk at the bottle bottom sediments, illustrate that atomization is poor.Exhausted capsule shells is taken out from suction apparatus, and precision is weighed (W2), with small brushes the residual powder of inside capsule wall is wiped away only, claims capsulae vacuus weight (W3) again.The computational methods of capsule 's content powder residual quantity are:
[(W2-W3)/(W1-W3)]×100％
Humidity effect and capsule wall attach test: get insulin inhaled powder spray, the accurate title, decide, and in 25 ℃ of room temperature underlying RH75% environment, takes out after 24 hours, once more the weighing capsules weight.Then powder is poured out, observed the variation of characters powder, and attach situation to understand capsule wall by the residual quantity of powder in the last method mensuration capsule.
Insulin powder spray of the present invention can capsule form use.The size of used capsule can be any model, and preferred model is less than No. 0, selects usually 1-4 number.The capsule of insulin dust cloud can not only carry out suitability for industrialized production easily, and is easy to carry.The amount of insulin powder is certain in the capsule, and inhalation dose is accurate when guaranteeing to use, and can prevent many suctions of patient or few the suction effectively.
The content of capsule provided by the present invention is by the powder constituent of average diameter less than 100 μ m.The average diameter of preferred powder is less than 10 μ m, and the average diameter of most preferred powder is less than 5 μ m, usually between 0.5-5 μ m
Spray drying is one of common method of preparation powder spray, because the powder of spray drying gained is thinner, can reach the requirement of inhalation, or can reach this requirement through comminution by gas stream slightly; Spray-dired process is very fast, and drug solution can change into dry powder by liquid state in the several seconds, can reduce the chance of microbial contamination on the one hand, and insulin is difficult for being destroyed by high temperature in the so short time on the other hand.In process of the test, also once attempted the method for relevant patent, insulin solutions is put 40 ℃ of oven dry, this process need 24 hours or longer time, increased the chance of microbial contamination greatly, also attempted freeze-drying method in addition, cycle is also more than 24 hours, in view of above comparison, selected the spray drying method that the production cycle shortens greatly for use.
According to the character of insulin, earlier insulin is dissolved in acid routinely, again pH value of solution is transferred to 7.0-7.5.Because insulin is equal solubilized in acid and meta-alkalescence solution, insulin dissolves comparatively fast and fully under acidity, but considers people's physiological adaption, so again pH is transferred to about 7.0-7.5, preferably transfers to the pH scope 7.4 of adaptation of human body.The consumption of water is more, and purpose is the solid content that reduces in the droplet, makes the gained powder thinner.Can remove insoluble composition and microorganism with 0.2 μ m filtering with microporous membrane.The operating condition of spray dryer mainly is with the yield that improves dry powder and to reduce its water content be target, repeatedly gropes to obtain, and the dry powder yield is more than 80% under the above-mentioned condition, and loss on drying is below 5%.
Find in the test that the throughput of nozzle is bigger, heal height and granularity of the yield of product is littler, when throughput increases 800ml/min by 400ml/min, yield can increase to about 60% by 33%, and particle diameter is reduced to below the 3 μ m by 12.5 μ m, so throughput is transferred to maximum horizontal (800ml/min).Each factor has designed with spray velocity (the pump speed index of control nozzle flow, P:10 the influence of product yield and character among the preparation technology in order further to investigate, 15,20), inlet temperature is (Inlet Temperature:90 ℃, 100 ℃, 110 ℃), wind speed (A): 70%, 80%, 90%, and quantity of solvent (40U * 500 a consumption 125ml, 250ml, 500ml) orthogonal test of four factors, three levels.In the index of investigating, yield (Recovery) is the ratio with inventory must measured of spray drying micropowder; Drawing wet weightening finish (Gained Weight) test and being placed on balance 24h under the RH75% for micropowder (about 1g) is weighed, the back of weighing is with the weight calculating before to moisture absorption of the weight that increases; Rounding property (Round Unity) is a major diameter and the ratio (D of minor axis
Long/ D
Short); Particle diameter is for directly measuring from electron microscope photo scanning.Rounding property and particle diameter are the meansigma methods of 10 above powders, and have considered the representativeness of sample.
Result of the test is shown in Table 3, and as seen each process conditions has bigger influence to sample yield and physical property.
Four factors, three horizontal quadrature test for data tables in table 3 technological process
Batch P import temperature A quantity of solvent yield draws wet weightening finish density rounding property angle of repose particle diameter
The No degree (℃) (%) (ml) (%) (g/g) g/ml (°) (μ m)
1 10 90 70 125 50.1 0.0743 0.218 51.34 1.01 3.75
2 10 100 80 250 40.9 0.0751 0.257 50.19 1.01 2.79
3 10 110 90 500 58.7 0.0716 0.275 53.13 1.01 2.24
4 15 90 80 500 43.1 0.0623 0.198 43.02 1.08 3.10
5 15 100 90 125 62.2 0.0316 0.257 29.74 1.02 2.93
6 15 110 70 250 63.3 0.0305 0.259 39.56 1.01 3.77
7 20 90 90 250 29.6 / 0.245 27.22 1.15 2.54
8 20 100 70 500 30 / 0.207 39.37 1.37 /
9 20 110 80 125 43.7 0.0371 0.22 43.36 1.09 2.00
(illustrate: be 500 capsules recipe quantities, being on close level of this quantity of solvent in 1000 250,500 and 1000ml)
Experiment shows: the relation of product recovery rate and nozzle flow velocity (P) is the closest, has only moderate spray velocity just to have the higher response rate, and response rate order from high to low is P15＞P10＞P20 in this test.P is too little or P is all unfavorable to yield too greatly.May be hour at P, spray velocity is slow, and the time is long, and loss is many; Spray velocity is too fast, and droplet has little time dry solidification, and part sticks on the chamber wall and causes damage.Second factor that influences the response rate is inlet temperature, and yield was higher when inlet temperature was higher; Quantity of solvent more also has higher recovery in addition, may be because quantity of solvent when big the granularity of powder less, be difficult for deposition.
Particulate rounding property is main relevant with quantity of solvent with nozzle flow velocity (P).P is littler, and the granule rounding property may be because nozzle flow velocity when less better, and it is less relatively that particle collides the probability of mutual adhesion mutually; Quantity of solvent is littler, and the concentration of solute is higher, molding easily in the dry run, and particulate rounding property is better.
Process conditions are little to the bulk density influence.
From result of the test, P and A are bigger to influence angle of repose of micropowder, and angle of repose was less when P and A were big.
Hygroscopicity and nozzle flow velocity (P) relation are bigger, and P is bigger, and hygroscopicity is littler.Lower in addition inlet temperature and less quantity of solvent all can reduce the moisture absorption weightening finish of micropowder.Grain diameter is main relevant with quantity of solvent, and quantity of solvent is bigger, and particle diameter is littler.
Because the atomizing effect by the insulin powder spray of the technical program preparation is good, so can utilize the commercially available treatment asthma and the suction powder unit of chronic bronchitis.For example use the inhaler of Shanghai balance pharmaceutical factory.What in fact this device play a part is capsule to be squeezed break.The medicated powder of general treatment asthma and chronic bronchitis is drawn into air flue can produce predetermined curative effect than the center, and the insulin powder spray is must suck alveolar region definite curative effect is just arranged.Insulin powder spray of the present invention can use by means of the suction powder unit of commercially available treatment asthma and chronic bronchitis, this physicochemical property that insulin powder spray of the present invention also is described is good, especially atomizing effect excellence, so that can use the former device of medicated powder that only can spray, insulin powder spray spray of the present invention is drawn to pulmonary to the air flue place.And insulin capsule of the present invention promptly uses hands to pinch brokenly, and content wherein can the air-flow effect when breathing enters alveolar and plays a role.This for outdoor or in emergency circumstances patient's self-administration be very easily.
In addition, described crowded broken capsular device can use repeatedly.Ghost can be abandoned behind the capsule 's content extinction, when using, in this device, insert a capsule more next time.This device can use repeatedly.
Insulin inhaled powder spray is to the blood sugar lowering test of rat
1 test objective
Contrast with subcutaneous injection administration and the blank adjuvant of suction, observe the hypoglycemic activity after rat is used insulin inhaled powder spray.And calculate the absorption fraction of insulin in the inhalant according to the percent that blood glucose reduces.
2 test materials
(1) animal: 72 of cleaning level SD rats, male, west, Chinese-foreign joint Shanghai pul-Bi Ke experimental animal center provides, body weight 180-200g, the animal quality certification number: Shanghai is moving closes the card word No. 152, uses after at least 2 days at this laboratory rearing.
(2) medicine: 1) insulin inhaled powder spray.China Medicine University trial-production, lot number 9907081 during use is poured out capsule 's content, with precision be 100,000/ analytical balance decide by the accurate title of dosage requirements of test, in another blank capsules of carefully packing into.
2) regular iletin.The Nanjing biochemical-pharmaceutical factory is produced, and specification: 40U/ml is diluted to 4U/ml with 0.01mol/L HCl during use.
3) blank adjuvant.All the components in the insulin inhaled powder spray except that the principal agent insulin becomes by identical prepared.
4) blood sugar detection test kit.Produce lot number 990405 by Shanghai Rongsheng Bioisystech Co., Ltd.
3 test methods
(1) the animal grouping is divided into 6 groups with 72 rats by body weight, 12 every group at random.Insulin inhaled powder spray 20U/kg, 10U/kg, 5U/kg and 4 dosage groups of 2.5U/kg are established in test respectively; Subcutaneous injection matched group, dosage are 5U/kg; Blank adjuvant capsule matched group.
(2) medication inhalation method is according to the report of relevant document, be specially: by the heavy medicated powder that accurately takes by weighing of animal body, insert in the capsulae vacuus, capsule is put into the sleeve pipe of an end band 12# syringe needle, with the 7# syringe needle bored a hole in the capsule two ends, the telescopic other end links to each other with syringe. before the rat experiment after the fasting 12 hours (freely drinking water), (45mg/kg) carries out intraperitoneal anesthesia with pentobarbital sodium, separate trachea, then above-mentioned 12# syringe needle is inserted in the trachea, in capsule, push air 2ml with syringe and be blown in the induced lung, and begin to clock after the medicated powder atomizing.Get blank blood before the rat administration, and respectively at after the administration 0.25,0.5,1.0,1.5,2.0,2.5,3.0,4.0,5.0,7.0h gets blood with capillary glass tube in the eyeground vein clump, and is centrifugal, isolates serum.
(3) blood-sugar level measuring is measured the blood sugar concentration of rat with the glucose oxidase-peroxidase method.
4 result of the tests
Blood sugar concentration after the rat medication
From table 4 to table 9 as seen, 4 dosage groups of insulin inhaled powder spray 15min behind the trachea inhalation, rat blood sugar concentration promptly has tangible reduction, after the administration about 0.5～2 hour drug effect reach maximum.From the blood glucose meansigma methods, 20,10,5 and 2.5U/kg dosage inhalation and 5U/kg dosage subcutaneous injection can make rat blood sugar be reduced to 14.0,25.7 respectively, 29.4,67.4 and 30.9mg/dL; After 2 hours, blood glucose progressively recovers.
The full name of last string AAC is in each table: Area Above The Curve, represent area on the blood glucose curve.Its implication is: after the medication blood sugar concentration to the curve of time mapping and medication before area between the glucose concentration level.
Blood sugar concentration (mg/dL) behind the table 4. rat pulmonary administration insulin 20U/kg
Time(h) AAC
0 0.25 0.5 1.0 1.5 2.0 2.5 3.0 4.0 5.0 7.0
Average 102.5 54.3 17.9 15.6 17.6 14.0 19.1 25.6 42.2 54.4 71.5 424.8
SD 8.8 10.7 8.4 9.8 12.4 13.4 16.8 20.5 19.4 11.8 5.0 57.1
Blood sugar concentration (mg/dL) behind the table 5 rat pulmonary administration insulin 10U/kg
Time(h) AAC
0 0.25 0.5 1.0 1.5 2.0 2.5 3.0 4.0 5.0 7.0
Average 109.5 75.5 43.1 26.0 25.7 37.0 40.2 53.1 71.1 73.1 86.2 314.8
SD 10.2 18.8 23.4 23.7 22.9 25.1 32.3 32.2 23.9 19.5 24.1 107.2
Blood sugar concentration behind the table 6 rat pulmonary administration insulin 5U/kg
Time(h) AAC
0 0.25 0.5 1.0 1.5 2.0 2.5 3.0 4.0 5.0 7.0
Average 96.6 54.5 45.1 38.3 29.4 36.0 55.3 66.0 73.1 85.2 92.0 214.7
SD 17.4 37.4 21.5 15.5 15.0 13.3 15.0 21.1 27.0 13.5 15.1 52.7
Blood sugar concentration (mg/dL) behind the table 7. rat pulmonary administration insulin 2.5U/kg
Time(h) AAC
No 0 0.25 0.5 1.0 1.5 2.0 2.5 3.0 4.0 5.0 7.0
Average 111.0 93.7 89.2 67.4 73.1 72.4 82.6 96.2 102.4 109.4 109.1 98.9
SD 10.1 10.2 14.8 13.1 15.4 12.1 15.9 14.9 24.2 16.3 9.6 31.7
Blood sugar concentration (mg/dL) behind the table 8. rat skin lower injection insulin 5U/kg
Time(h) AAC
0 0.25 0.5 1.0 1.5 2.0 2.5 3.0 4.0 5.0 7.0
Average 99.8 42.8 34.9 33.1 32.4 30.9 54.2 66.4 91.2 92.9 97.8 214.8
SD 13.4 15.6 18.1 7.1 17.3 19.2 14.8 11.9 30.2 18.0 16.5 40.0
Blood sugar concentration (mg/dL) behind the blank adjuvant of table 9. rat pulmonary administration
Time(h)
0 0.25 0.5 1.0 1.5 2.0 2.5 3.0 4.0 5.0 7.0
Average 108.0 107.6 109.2 111.0 110.5 108.6 108.2 108.2 110.9 111.4 109.4
SD 9.25 7.10 7.70 6.99 7.55 7.19 7.00 9.32 6.99 7.71 8.99
The specific embodiment
Supplementary material source and quality standard:
95 editions two Xuzhou biochemical-pharmaceutical factories of the medicinal Chinese Pharmacopoeia of insulin
95 editions two Lianyun Harbour system iodine factories of the medicinal Chinese Pharmacopoeia of mannitol
The medicinal the Sanitation Ministry medicine standard of L-threonine Tianjin aminoacid company
The medicinal the Sanitation Ministry medicine standard of L leucine Tianjin aminoacid company
95 editions two Sichuan morning twilight medical high polymer pharmaceutical factories of the medicinal Chinese Pharmacopoeia of citric acid
95 editions two Mingxing Pharmaceutical Factory, Guangzhous of the medicinal Chinese Pharmacopoeia of sodium citrate
Embodiment 1:
Get citric acid 0.18g and add in about 200ml water and make dissolving, add Insulin 3 g, stir and add an amount of dilute hydrochloric acid insulin is all dissolved, must solution 1.Will mannitol 21.0g, threonine 6.0g and sodium citrate 3.6g add in about 400ml water and make dissolving, must solution 2; Solution 1 and solution 2 are mixed, add water to 2000ml, transfer about pH to 7.4, constantly be stirred to the solution clarification, with 0.2 μ m filtering with microporous membrane, spray drying with diluted sodium hydroxide solution.Condition is 100 ℃ of inlet temperatures, 65 ℃ of outlet temperatures, throughput 90%, nozzle air flow velocity 800ml/min.White insulin-containing powder, measure insulin content, be sub-packed in the hard capsule promptly.
Embodiment 2:
Get insulin 1.5g, in 100ml, add an amount of 0.1mol/L hydrochloric acid insulin is all dissolved, get solution 1.To make dissolving in the about 200ml water of mannitol 9g, leucine 4.5g adding, get solution 2; Solution 1 and solution 2 are mixed, add water to 1000ml, transfer about pH to 7.4, constantly be stirred to the solution clarification, with 0.2 μ m filtering with microporous membrane, spray drying with diluted sodium hydroxide solution.Condition is 100 ℃ of inlet temperatures, 65 ℃ of outlet temperatures, throughput 90%, nozzle air flow velocity 800ml/min.White insulin-containing powder, measure insulin content, be sub-packed in the hard capsule promptly.
Embodiment 3:
Get citric acid and add in about 100ml water and make dissolving, add insulin 1.5g, stir and add an amount of dilute hydrochloric acid insulin is all dissolved, must solution 1.Will mannitol 12g, threonine 1.5g and sodium citrate 1.8g add in about 200ml water and make dissolving, must solution 2; Solution 1 and solution 2 are mixed, add water to 1000ml, transfer about pH to 7.4, constantly be stirred to the solution clarification, with 0.2 μ m filtering with microporous membrane, spray drying with diluted sodium hydroxide solution.Condition is 110 ℃ of inlet temperatures, 70 ℃ of outlet temperatures, throughput 90%, nozzle air flow velocity 800ml/min.White insulin-containing powder, measure insulin content, be sub-packed in the hard capsule promptly.
Spray-dried powders morphologic observation result: with optical microscope and Electronic Speculum the capsule 's content powder is observed respectively, visible this powder is one tiny granule under 1000 times optical microscope, no adhesion, no agglomerate, good dispersion is a kind of spheroidal structure.
Spray-dried powders laser particle size measurement result: Britain Malvern Instruments Ltd. laser granulometry has carried out granulometry to the capsule 's content powder of different lot numbers, the above-mentioned sample granularity of result less than the shared percentage ratio of the part of 5 μ m all greater than 70%.
In order to investigate the destruction degraded whether preparation process causes insulin, the solution of spray drying proinsulin and adjuvant and the insulin-containing powder after the spray drying are measured with the HPLC method.Method is an amount of for getting above-mentioned solution or powder, makes the solution that insulin concentration is equivalent to 40U/ml, calculates the relative amount of insulin content and impurity by peak area method.The results are shown in Table shown in 10, visible content of insulin does not have tangible change, and impurity level is compared with the insulin raw material not have significantly to be increased.
Table 10 preparation process is to the influence of insulin content and impurity level
| Before the spray drying | After the spray drying | |
| Content impurity | 100.1％ 3.26％ | 98.0％ 3.40％ |
Claims (8)
1, a kind of insulin powder spray is characterized in that its Main Ingredients and Appearance weight ratio is:
1 part of insulin, 6～7 parts in mannitol, 0.5～3 part of threonine, L-isoleucine and/or leucine.
2,, it is characterized in that mainly forming by weight: 1 part of insulin, 6～7 parts in mannitol, 0.5～3 part of threonine by following composition according to the described insulin powder spray of claim 1.
3,, it is characterized in that mainly by following composition by weight than forming: 1 part of insulin, 7 parts in mannitol, 2 parts of leucines according to the described insulin powder spray of claim 1.
4, a kind of preparation method of insulin powder spray, with 1 part of the insulin of weight ratio, 6～7 parts in mannitol, 0.5～3 part of threonine, L-isoleucine and/or leucine mix with water, mixed liquor by weight/volume ratio meter concentration is 0.1-5%, spray drying.
5, according to the preparation method of the described insulin powder spray of claim 4, it is characterized in that: mixed liquor by weight/volume ratio meter concentration is 0.1～5%, the spray drying inlet temperature is 100～120 ℃, outlet temperature is 60～70 ℃, nozzle flow velocity 800L/H.
6, according to the preparation method of the described insulin powder spray of claim 5, it is characterized in that: the by weight/volume of mixed liquid concentration is 1～2%, and the spray drying inlet temperature is 110 ℃, and outlet temperature is 65 ℃, nozzle flow velocity 800L/H.
7, according to the preparation method of the described insulin powder spray of claim 6, it is characterized in that: with 1 part of weight ratio insulin, 7 parts in mannitol, 2 parts of threonine mix with water, and the by weight/volume of mixed liquid concentration is 1.7%, spray drying, the gained insulin powder incapsulates.
8, according to the preparation method of the described insulin powder spray of claim 6, it is characterized in that: 1 part of the insulin of weight ratio, 6 parts in mannitol, 3 parts of leucines mix with water, and the by weight/volume of mixed liquid concentration is 1.6%, spray drying, the gained insulin powder incapsulates.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021125139A CN1168496C (en) | 2002-01-09 | 2002-01-09 | Powder mist for pulmonary administration of insulin and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021125139A CN1168496C (en) | 2002-01-09 | 2002-01-09 | Powder mist for pulmonary administration of insulin and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1372973A CN1372973A (en) | 2002-10-09 |
| CN1168496C true CN1168496C (en) | 2004-09-29 |
Family
ID=4742067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021125139A Expired - Fee Related CN1168496C (en) | 2002-01-09 | 2002-01-09 | Powder mist for pulmonary administration of insulin and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1168496C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100484543C (en) * | 2004-12-21 | 2009-05-06 | 四川迪康科技药业股份有限公司 | Medicament composition for treating hepatitis, prepartion method and use |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1311868C (en) * | 2003-06-10 | 2007-04-25 | 上海兴康医药研究开发有限公司 | Preparing process of insulin powder inhalant |
| TWI590838B (en) * | 2014-04-18 | 2017-07-11 | 林信湧 | Inhalation-type pharmaceutical composition for diabetes and preparation method thereof |
| CN105796534B (en) * | 2014-12-31 | 2019-06-28 | 深圳翰宇药业股份有限公司 | A kind of Dapagliflozin inhalation powder spray and preparation method thereof |
| CN114727969B (en) * | 2021-02-05 | 2023-06-20 | 浙江萃泽医药科技有限公司 | A kind of inhalable drug powder preparation and preparation method thereof |
| WO2022166458A1 (en) * | 2021-02-05 | 2022-08-11 | 浙江仙琚萃泽医药科技有限公司 | Inhalable pharmaceutical powder formulation and preparation method therefor |
-
2002
- 2002-01-09 CN CNB021125139A patent/CN1168496C/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100484543C (en) * | 2004-12-21 | 2009-05-06 | 四川迪康科技药业股份有限公司 | Medicament composition for treating hepatitis, prepartion method and use |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1372973A (en) | 2002-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1170527C (en) | Inhaled therapeutic agent containing parathyroid hormone (PTH) | |
| US20180221280A1 (en) | Heat-stable dry powder pharmaceutical compositions and methods | |
| CN104755097A (en) | Method and composition for treating hyperglycemia | |
| CN1314818A (en) | Method for administering insulinotropic peptides | |
| CN1317977A (en) | Dry powder active agent pulmonary delivery | |
| CN1446077A (en) | Inhaleable spray dried 4-holix bundle protein powders having minimized aggregation | |
| CN101422436B (en) | Dry powder composite for suction | |
| CN114949183B (en) | A kind of telpoetide powder mist and preparation method thereof | |
| CN114727969B (en) | A kind of inhalable drug powder preparation and preparation method thereof | |
| CN1168496C (en) | Powder mist for pulmonary administration of insulin and preparation method thereof | |
| CN1662244A (en) | Powdered Inhalation Composition | |
| CN100349611C (en) | Redfish calcitonin inhalation powder-atomizing agent and preparing method | |
| CN116763763B (en) | A semaglutide inhalation spray and a preparation method thereof | |
| CN1439360A (en) | Dry powder composition for improvement of effective position medical deposit | |
| CN105796534B (en) | A kind of Dapagliflozin inhalation powder spray and preparation method thereof | |
| CN106668837A (en) | Exenatide dry-powder inhalant and preparation method thereof | |
| CN1642533A (en) | Powdery medicinal compositions for inhalation and process for producing the same | |
| CN101401793B (en) | Capsule type inhalation dust cloud agent | |
| CN101474399A (en) | Insulin powder spray for lung inhalation and preparation method thereof | |
| CN101045158A (en) | Insulin analog dry powder composition and its preparing method | |
| CN1293895C (en) | Oral disintegration tablet for laryngopathy and its preparing method | |
| CN1593414A (en) | Powder inhalation of tiotropium bromide capsule type and its preparation method | |
| CN1720911A (en) | Pharmaceutical composition containing ambroxol and erdosteine or acetylcysteine and application thereof | |
| CN113940925B (en) | Arbidol mesylate freeze-drying agent for aerosol inhalation | |
| TW576750B (en) | Pharmaceutical composition for respiratory/pulmonary delivery of insulin and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Shanghai Biolaxy Medical Technology Co., Ltd. Assignor: China Pharmaceutical University Contract fulfillment period: 2008.5.20 to 2022.1.8 contract change Contract record no.: 2008990000173 Denomination of invention: Powder snuff of insulin for administration of lung and its preparing process Granted publication date: 20040929 License type: exclusive license Record date: 2008.6.30 |
|
| LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENCE; TIME LIMIT OF IMPLEMENTING CONTACT: 2008.5.20 TO 2022.1.8 Name of requester: SHANGHAI BLUE HEART MEDICAL TECHNOLOGY CO., LTD. Effective date: 20080630 |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20040929 Termination date: 20120109 |